<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolaou, K.A.a</style></author><author><style face="normal" font="default" size="100%">Liapis, V.b</style></author><author><style face="normal" font="default" size="100%">Evdokiou, A.b</style></author><author><style face="normal" font="default" size="100%">Constantinou, C.c</style></author><author><style face="normal" font="default" size="100%">Magiatis, P.d</style></author><author><style face="normal" font="default" size="100%">Skaltsounis, A.L.d</style></author><author><style face="normal" font="default" size="100%">Koumas, L.e</style></author><author><style face="normal" font="default" size="100%">Costeas, P.A.e</style></author><author><style face="normal" font="default" size="100%">Constantinou, A.I.a</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells</style></title><secondary-title><style face="normal" font="default" size="100%">Biochemical and Biophysical Research Communications</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">6 bromoindirubin 3’oxime</style></keyword><keyword><style  face="normal" font="default" size="100%">7 bromoindirubin 3’oxime</style></keyword><keyword><style  face="normal" font="default" size="100%">antineoplastic alkaloid</style></keyword><keyword><style  face="normal" font="default" size="100%">apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Breast Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">cancer cell</style></keyword><keyword><style  face="normal" font="default" size="100%">cancer invasion</style></keyword><keyword><style  face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style  face="normal" font="default" size="100%">caspase 8</style></keyword><keyword><style  face="normal" font="default" size="100%">caspase 9</style></keyword><keyword><style  face="normal" font="default" size="100%">cell assay</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Cycle</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style  face="normal" font="default" size="100%">cell viability</style></keyword><keyword><style  face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">G2 phase cell cycle checkpoint</style></keyword><keyword><style  face="normal" font="default" size="100%">human</style></keyword><keyword><style  face="normal" font="default" size="100%">human cell</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Indoles</style></keyword><keyword><style  face="normal" font="default" size="100%">M phase cell cycle checkpoint</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Invasiveness</style></keyword><keyword><style  face="normal" font="default" size="100%">Oximes</style></keyword><keyword><style  face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style  face="normal" font="default" size="100%">upregulation</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.scopus.com/inward/record.url?eid=2-s2.0-84865186578&amp;partnerID=40&amp;md5=39c3549229e162b461eb11eabf6d57f0</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">425</style></volume><pages><style face="normal" font="default" size="100%">76-82</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Indirubin derivatives gained interest in recent years for their anticancer and antimetastatic properties. The objective of the present study was to evaluate and compare the anticancer properties of the two novel bromo-substituted derivatives 6-bromoindirubin-3’-oxime (6BIO) and 7-bromoindirubin-3’-oxime (7BIO) in five different breast cancer cell lines. Cell viability assays identified that 6BIO and 7BIO are most effective in preventing the proliferation of the MDA-MB-231-TXSA breast cancer cell line from a total of five breast cancer cell lined examined. In addition it was found that the two compounds induce apoptosis via different mechanisms. 6BIO induces caspase-dependent programmed cell death through the intrinsic (mitochondrial) caspase-9 pathway. 7BIO up-regulates p21 and promotes G2/M cell cycle arrest which is subsequently followed by the activation of two different apoptotic pathways: (a) a pathway that involves the upregulation of DR4/DR5 and activation of caspase-8 and (b) a caspase independent pathway. In conclusion, this study provides important insights regarding the molecular pathways leading to cell cycle arrest and apoptosis by two indirubin derivatives that can find clinical applications in targeted cancer therapeutics. © 2012 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">cited By (since 1996)3</style></notes></record></records></xml>